Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Enlivex Therapeutics Ltd
ENLV | US
1.16
USD0.02
1.75%
ENLV | US
Loading StockChartView...
About Enlivex Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.16
Open
1.12
High
1.17
Low
1.12
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona Israel.
View LessENLV | US
Risk
66.1
Sharpe
-0.05
Luna's Score
49/100
Recommendation
Hold
Luna says (ENLV | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
77.1%1 month
66.1%3 months
76.1%6 months
69.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.22
Debt to equity
0.03
Debt to assets
0.03
Ent. to EBITDA
-1.49
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-17.89M
MarketCap
24.83M
MarketCap(USD)
24.83M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-61.17
Short ratio
0.70
Short perc.
0.52
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.25
Range1M
0.25
Range3M
0.60
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.41
Price X volume
113.98K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.49 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 76.13 | 72.80 | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 24.83M | 3.66B | Emerging |
